3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
5
Neoplasms
2
Thrombosis
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
37
Radiotherapy
20
Bevacizumab
14
Carboplatin
10
Magnetic Resonance Spectroscopy
9
Carmustine
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Irinotecan
8
Filgrastim
7
Cyclophosphamide
6
Cisplatin
6
Etoposide
5
sargramostim
4
Vincristine
4
Thiotepa
4
Surgical Procedures, Operative
4
Specimen Handling
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Lomustine
4
Everolimus
4
Chemotherapy, Adjuvant
4
trametinib
3
aldesleukin
3
Topotecan
3
Thalidomide
3
Tamoxifen
3
Sunitinib
3
Procarbazine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Astrocytoma
×
apixaban
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled